Therefore, the development of a drug with high selectivity for c-MYC G4 structure and robust anti-tumor activity holds promise as a reliable choice for TNBC therapy, bearing crucial significance in improving the prognosis of TNBC patients [12]. Here, MYC is linked to neoplasm.